Publicacións nas que colabora con Vicente Escudero Vilaplana (16)

2022

  1. Medication guide for the perioperative management of oral antineoplastic agents in cancer patients

    Expert Opinion on Drug Safety, Vol. 21, Núm. 1, pp. 107-119

2020

  1. Design of the functional requirements of a smartphone app for patients receiving oral antineoplastic agents: The e-OncoSalud® app

    Journal of Oncology Pharmacy Practice, Vol. 26, Núm. 1, pp. 105-115

  2. Effect of a Mobile App for the Pharmacotherapeutic Follow-Up of Patients with Cancer on Their Health Outcomes: Quasi-Experimental Study

    JMIR mHealth and uHealth, Vol. 8, Núm. 10

  3. Novel mobile application for direct communication between pharmacists and patients treated with oral antineoplastic agents

    American Journal of Health-System Pharmacy, Vol. 77, Núm. 17, pp. 1393-1402

2017

  1. Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct-acting antivirals: The GRUviC project

    International Journal of Clinical Practice, Vol. 71, Núm. 8

  2. Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents

    European Journal of Cancer Care, Vol. 26, Núm. 3

2016

  1. Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice

    Annals of Pharmacotherapy, Vol. 50, Núm. 11, pp. 901-908

  2. Guiding pharmacist clinical interviews: A safety tool to support the education of patients treated with oral antineoplastic agents

    Expert Opinion on Drug Safety, Vol. 15, Núm. 4, pp. 427-435

  3. Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction

    International Journal of Clinical Pharmacy, Vol. 38, Núm. 2, pp. 280-288

  4. Smartphone applications for cancer patients; what we know about them?

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 40, Núm. 1, pp. 25-35

2015

  1. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice

    International Journal of Clinical Pharmacy, Vol. 37, Núm. 5, pp. 808-814

2014

  1. Increased INR after gefitinib and acenocoumarol co-administration

    European Review for Medical and Pharmacological Sciences, Vol. 18, Núm. 12, pp. 1720-1722

  2. Seguimiento del estado nutricional y calidad de vida de pacientes que inician tratamiento con inhibidores tirosin kinasa

    Nutricion Hospitalaria, Vol. 30, Núm. 5, pp. 1092-1100

2013

  1. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: Dosing patterns and effectiveness in daily clinical practice

    Clinical and Experimental Rheumatology, Vol. 31, Núm. 4, pp. 559-565

  2. Oral ammonium chloride, treatment in severe metabolic alkalosis

    Latin American Journal of Pharmacy, Vol. 32, Núm. 10, pp. 1578-1580

2012

  1. Influence on effectiveness of early treatment with anti-TNF therapy in rheumatoid arthritis

    Journal of Pharmacy and Pharmaceutical Sciences, Vol. 15, Núm. 3, pp. 355-360